Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company`s product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab (AB154), its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics (Cayman) Inc. The company was founded in 2015 and is based in Hayward, California.
Website: arcusbio.com



Growth: Good revenue growth rate 16.1%, there is slowdown compared to average historical growth rates 51.7%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -96.1%. On average the margin is decreasing steadily. Gross margin is high, +100.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.05 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 227.2% higher than minimum and 13.9% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -1.1x by EV / Sales multiple

Insiders: For the last 3 months insiders sold company shares on $7.2 mln (-0.586% of cap.)

Key Financials (Download financials)

Ticker: RCUS
Share price, USD:  (0.0%)22.48
year average price 13.68  


year start price 12.60 2025-02-08

min close price 6.87 2025-04-04

max close price 26.10 2025-11-28

current price 22.48 2026-02-07
Common stocks: 54 787 118

Dividend Yield:  0.0%
EV / Sales: 0.6x
Margin (EBITDA LTM / Revenue): -96.1%
Fundamental value created in LTM:
Market Cap ($m): 1 232
Net Debt ($m): -1 091
EV (Enterprise Value): 141
Price to Book: 2.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-26businesswire.com

Arcus Biosciences Announces New Employment Inducement Grants

2026-01-14seekingalpha.com

Arcus Biosciences, Inc. (RCUS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-15zacks.com

RCUS Stock Down on Decision to Discontinue GILD Partnered Study

2025-12-12benzinga.com

Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug

2025-12-09businesswire.com

Arcus Biosciences Announces New Employment Inducement Grants

2025-12-03seekingalpha.com

Arcus Biosciences, Inc. (RCUS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

2025-11-02fool.com

Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan

2025-10-30businesswire.com

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

2025-10-19businesswire.com

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

2025-10-12businesswire.com

Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-10-28 2025-08-06 2024-11-06 2024-08-08 2024-05-08 2023-11-07 2023-08-07 2023-05-09 2022-11-02
acceptedDate 2025-10-28 16:12:26 2025-08-06 16:13:45 2025-02-25 16:09:12 2024-11-06 16:25:33 2024-08-08 16:15:01 2024-05-08 16:08:38 2024-02-21 16:16:29 2023-11-07 16:11:43 2023-08-07 08:13:27 2023-05-09 16:15:52 2023-02-28 16:18:59 2022-11-02 16:11:59 2022-02-23 16:16:33 2021-02-24 19:10:06
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 26M 160M 258M 48M 39M 145M 117M 32M 29M 25M 112M 34M 383M 78M
costOfRevenue 2M 0 0 0 2M 3M 0 3M 0 0 0 0 0 0
grossProfit 24M 160M 258M 48M 37M 142M 117M 29M 29M 25M 112M 34M 383M 78M
grossProfitRatio 0.923 1 1 0.949 0.979 0.906 1 1 1
researchAndDevelopmentExpenses 141M 139M 448M 123M 115M 109M 340M 82M 84M 81M 288M 77M 257M 159M
generalAndAdministrativeExpenses 27M 29M 120M 30M 30M 32M 117M 30M 28M 30M 104M 26M 72M 43M
sellingAndMarketingExpenses 0 0 0 0 -2M 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 27M 29M 120M 30M 28M 32M 117M 30M 28M 30M 104M 26M 72M 43M
otherExpenses -2M 0 20M 0 0 20M 0 0 0 0 0 0 0 0
operatingExpenses 166M 168M 588M 153M 143M 141M 457M 112M 112M 111M 392M 103M 329M 202M
costAndExpenses 168M 168M 588M 153M 145M 141M 457M 112M 112M 111M 392M 103M 329M 202M
interestIncome 10M 10M 52M 14M 13M 13M 41M 12M 9M 9M 16M 5M 1 000 000 1 000 000
interestExpense 3M 2M 4M 1 000 000 0 1 000 000 2M 1 000 000 0 1 000 000 2M 535 000 0 0
depreciationAndAmortization 2M 2M 10M 2M 2M 3M 8M 12M 2M 9M 6M 7M 4M 3M
ebitda -130M 4M -269M -89M -91M 20M -291M -68M -74M -77M -258M -63M 59M -120M
ebitdaratio -5 0.025 -1.854 -2.667 0.138 -2.125 -2.552 -3.08 -1.871
operatingIncome -142M -8M -330M -105M -106M -16M -340M -80M -83M -86M -280M -69M 54M -124M
operatingIncomeRatio -5.462 -0.05 -2.188 -2.718 -0.11 -2.5 -2.862 -3.44 -2.067
totalOtherIncomeExpensesNet 7M 0 47M 13M 13M -20M 39M 11M 9M 8M 14M 4M 1 000 000 1 000 000
incomeBeforeTax -135M -8M -283M -92M -93M -4M -301M -69M -74M -78M -266M -65M 55M -123M
incomeBeforeTaxRatio -5.192 -0.05 -1.917 -2.385 -0.028 -2.156 -2.552 -3.12 -1.933
incomeTaxExpense 0 0 1 000 000 0 0 1 000 000 6M 2M 1 000 000 2M 1 000 000 -4M 2M 0
netIncome -135M -8M -283M -92M -93M -4M -307M -71M -75M -80M -267M -60M 53M -123M
netIncomeRatio -5.192 -0.05 -1.917 -2.385 -0.028 -2.219 -2.586 -3.2 -1.8
eps -1.27 0.043 -3.14 -1.01 -1.02 -0.046 -4.15 -0.95 -1.02 -1.1 -3.71 -0.84 0.76 -2.13
epsdiluted -1.27 0.043 -1.01 -1.02 -0.046 -0.95 -1.02 -1.1 -0.84
weightedAverageShsOut 107M 106M 90M 91M 91M 86M 74M 75M 73M 73M 72M 72M 69M 55M
weightedAverageShsOutDil 107M 107M 90M 91M 91M 86M 74M 75M 73M 73M 72M 72M 74M 55M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-25 2024-02-21 2023-02-28 2022-02-23 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 48M 39M 14M 1 000 000 1 000 000
ebit -279M -299M -264M 55M -123M
nonOperatingIncomeExcludingInterest -51M -41M -16M -1 000 000 -1 000 000
netIncomeFromContinuingOperations -284M -307M -267M 53M -123M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 1 000 000 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -283M -307M -267M 53M -123M
epsDiluted -3.14 -4.15 -3.71 0.71 -2.13

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-10-28 2025-08-06 2024-11-06 2024-08-08 2024-05-08 2023-11-07 2023-08-07 2023-05-09 2022-11-02
acceptedDate 2025-10-28 16:12:26 2025-08-06 16:13:45 2025-02-25 16:09:12 2024-11-06 16:25:33 2024-08-08 16:15:01 2024-05-08 16:08:38 2024-02-21 16:16:29 2023-11-07 16:11:43 2023-08-07 08:13:27 2023-05-09 16:15:52 2023-02-28 16:18:59 2022-11-02 16:11:59 2022-02-23 16:16:33 2021-02-24 19:10:06
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 238M 248M 150M 201M 156M 185M 127M 184M 230M 238M 206M 218M 148M 173M
shortTermInvestments 593M 663M 828M 888M 813M 810M 632M 615M 700M 716M 803M 831M 351M 555M
cashAndShortTermInvestments 831M 911M 978M 1 089M 969M 995M 759M 950M 1 010M 1 044M 1 009M 1 049M 499M 729M
netReceivables 14M 20M 25M 21M 33M 40M 42M 56M 37M 36M 43M 31M 747M 2M
inventory 0 0 0 0 0 0 0 -207M -80M -90M 0 0 0 0
otherCurrentAssets 12M 15M 13M 17M 20M 29M 30M 83M 19M 25M 14M 22M 15M 4M
totalCurrentAssets 857M 946M 1 016M 1 127M 1 022M 1 064M 831M 882M 986M 1 015M 1 066M 1 101M 1 262M 736M
propertyPlantEquipmentNet 42M 44M 47M 48M 49M 51M 51M 50M 45M 37M 135M 136M 137M 24M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 10M 16M 14M 2M 49M 100M 107M 151M 80M 90M 134M 143M 185M 7M
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 65M 69M 73M 75M 66M 78M 106M 108M 109M 112M 10M 14M 8M 6M
totalNonCurrentAssets 117M 129M 134M 125M 164M 229M 264M 309M 234M 239M 279M 293M 330M 36M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 974M 1 075M 1 150M 1 252M 1 186M 1 293M 1 095M 1 191M 1 220M 1 254M 1 345M 1 394M 1 592M 772M
accountPayables 42M 29M 18M 13M 15M 16M 17M 17M 12M 28M 20M 11M 10M 16M
shortTermDebt 13M 12M 0 11M 11M 11M 0 9M 57M 0 3M 0 5M 3M
taxPayables 0 0 1 000 000 0 0 0 0 3M 2M 1 000 000 0 18 000 2M 0
deferredRevenue 52M 71M 85M 105M 113M 124M 91M 103M 103M 97M 97M 103M 102M 75M
otherCurrentLiabilities 128M 98M 14M 86M 60M 53M 39M 71M 8M 54M 48M 63M 30M 20M
totalCurrentLiabilities 235M 210M 226M 215M 199M 204M 184M 200M 180M 179M 193M 177M 166M 122M
longTermDebt 98M 97M 48M 47M 0 128M 0 115M 0 0 0 119M 0 0
deferredRevenueNonCurrent 53M 60M 234M 0 214M 242M 307M 326M 330M 330M 355M 383M 462M 123M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 -20M -128M 0 -115M 0 0 0 0 0 0
otherNonCurrentLiabilities 152M 159M 157M 425M 138M 140M 142M 145M 144M 145M 23M 404M 5M 10M
totalNonCurrentLiabilities 303M 316M 439M 472M 352M 382M 449M 471M 474M 475M 495M 518M 584M 148M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 13M 12M 12M 11M 11M 11M 11M 9M 0 0 117M 119M 117M 15M
totalLiabilities 538M 526M 665M 687M 551M 586M 633M 671M 654M 654M 688M 695M 750M 270M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 1 815M 1 793M 1 617M 1 602M 1 582M 1 561M 1 311M 1 291M 1 267M 1 226M 1 206M 7000 7000 6000
retainedEarnings -1 379M -1 244M -1 132M -1 038M -946M -853M -849M -768M -697M -622M -542M -475M -275M -328M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 1 000 000 -1 000 000 -1 000 000 0 -3M -4M -4M -7M -10M -1M 44 000
othertotalStockholdersEquity 0 0 0 0 0 0 0 0 1 183M
totalStockholdersEquity 436M 549M 485M 565M 635M 707M 462M 520M 566M 600M 657M 699M 841M 502M
totalEquity 436M 549M 485M 565M 635M 707M 462M 520M 566M 600M 657M 699M 841M 502M
totalLiabilitiesAndStockholdersEquity 974M 1 075M 1 252M 1 186M 1 293M 1 191M 1 220M 1 254M 1 394M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 974M 1 075M 1 150M 1 252M 1 186M 1 293M 1 095M 1 191M 1 220M 1 254M 1 345M 1 394M 1 592M 772M
totalInvestments 603M 679M 842M 890M 862M 910M 739M 766M 780M 806M 937M 974M 536M 562M
totalDebt 111M 109M 60M 58M 11M 11M 11M 9M 0 0 120M 119M 122M 18M
netDebt -127M -139M -90M -143M -145M -174M -116M -175M -230M -238M -86M -98M -26M -155M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-25 2024-02-21 2023-02-28 2022-02-23 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 20M 38M 39M 745M 1M
otherReceivables 5M 4M 4M 2M 649 000
prepaids 0 0 0 900 000 1 000 000
totalPayables 19M 17M 20M 12M 16M
otherPayables 1 000 000 0 0 2M 0
accruedExpenses 96M 26M 25M 17M 9M
capitalLeaseObligationsCurrent 12M 11M 0 0 0
capitalLeaseObligationsNonCurrent 0 0 117M 117M 15M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 0 0 0 1 118M 830M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS RCUS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-10-28 2025-08-06 2024-11-06 2024-08-08 2024-05-08 2023-11-07 2023-08-07 2023-05-09 2022-11-02
acceptedDate 2025-10-28 16:12:26 2025-08-06 16:13:45 2025-02-25 16:09:12 2024-11-06 16:25:33 2024-08-08 16:15:01 2024-05-08 16:08:38 2024-02-21 16:16:29 2023-11-07 16:11:43 2023-08-07 08:13:27 2023-05-09 16:15:52 2023-02-28 16:18:59 2022-11-02 16:11:59 2022-02-23 16:16:33 2021-02-24 19:10:06
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -135M 0 -283M -92M -93M -4M -307M -71M -75M -80M -267M -65M 53M -123M
depreciationAndAmortization 2M 2M 10M 2M 2M 3M 8M 1 000 000 2M 2M 14M 2M 4M 4M
deferredIncomeTax 0 0 0 0 0 0 0 -29M 13M 0 0 0 5M 0
stockBasedCompensation 14M 15M 76M 19M 20M 20M 73M 18M 18M 19M 0 16M 55M 22M
changeInWorkingCapital 21M -148M 22M 56M -19M -37M -71M -9M -13M -38M 623M -35M -376M 208M
accountsReceivables 4M 0 28M 12M 7M 13M 15M 11M 0 0 704M 7M -17M -917 000
inventory 0 0 0 0 0 0 0 6M 0 0 0 0 14M 21M
accountsPayables 13M 8M 3M -1 000 000 0 -1 000 000 -1 000 000 6M -19M 10M 8M -12M -5M 9M
otherWorkingCapital 4M -156M -9M 45M -26M -42M -85M -32M 19M -48M -89M -30M -368M 178M
otherNonCashItems 1 000 000 -2M 5M 41M 13M 2M -9M 27M -2M -1 000 000 68M 966 000 3M -46 000
netCashProvidedByOperatingActivities -97M -133M -170M 26M -94M -2M -306M -63M -57M -98M 438M -81M -256M 111M
investmentsInPropertyPlantAndEquipment 0 0 -6M -1 000 000 0 -4M -24M -10M -5M -3M -6M -1M -26M -3M
acquisitionsNet 0 0 0 0 0 0 0 -21M 0 0 0 0 -22M 431M
purchasesOfInvestments -165M -161M -1 043M -278M -206M -387M -788M -280M -239M -154M -1 241M -322M -719M -740M
salesMaturitiesOfInvestments 244M 298M 965M 250M 269M 222M 1 006M 301M 270M 286M 837M 344M 741M 308M
otherInvestingActivites 0 0 0 63M -165M 21M 0 0 3M
netCashUsedForInvestingActivites 79M 137M -29M 63M -169M 11M 26M 129M 23M
debtRepayment 0 49M 0 0 0 0 0 0 0
commonStockIssued 8M 3M -3M 3M 228M 10M 19M 1 000 000 0
commonStockRepurchased 0 0 0 1 000 000 -1 000 000 0 0 0 0 0 0 0 -6000 -54 000
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 48M 2M 1 000 000 -4M 4M 0 3M
netCashUsedProvidedByFinancingActivities 8M 52M 48M 2M 229M 6M 23M 1 000 000 3M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 26M 0 86 000 0 0 0
netChangeInCash -10M 56M 23M 48M -29M 58M -79M -46M -8M 32M 58M -55M -23M 115M
cashAtEndOfPeriod 241M 248M 153M 204M 156M 188M 130M 187M 233M 241M 206M 221M 151M 174M
cashAtBeginningOfPeriod 251M 192M 130M 156M 185M 130M 209M 233M 241M 209M 148M 276M 174M 58M
operatingCashFlow -97M -133M -170M 26M -94M -2M -306M -63M -57M -98M 438M -81M -256M 111M
capitalExpenditure 0 0 -6M -1 000 000 0 -4M -24M -10M -5M -3M -6M -1M -26M -3M
freeCashFlow -97M -133M -176M 25M -94M -6M -330M -73M -62M -101M 432M -82M -282M 108M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-25 2024-02-21 2023-02-28 2022-02-23 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 -3M 22M -431M
netCashProvidedByInvestingActivities -84M 194M -413M -4M -434M
netDebtIssuance 47M 0 10M 5M 0
longTermNetDebtIssuance 47M 0 0 5M 0
shortTermNetDebtIssuance 0 0 10M 0 0
netStockIssuance 228M 25M 23M 220M 434M
netCommonStockIssuance 228M 25M 23M 220M 434M
commonStockIssuance 228M 25M 23M 220M 434M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 2M 8M 0 12M 5M
netCashProvidedByFinancingActivities 277M 33M 33M 237M 439M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q1
2025-05-06 ET (fiscal 2025 q1)
2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q1
2024-05-08 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)

SEC forms

Show financial reports only

SEC form 8
2025-11-03 21:17 ET
Arcus Biosciences published news for 2025 q3
SEC form 8
2025-11-03 21:17 ET
Arcus Biosciences published news for 2025 q3
SEC form 8
2025-11-03 21:17 ET
Arcus Biosciences published news for 2025 q3
SEC form 10
2025-10-28 20:12 ET
Arcus Biosciences reported for 2025 q3
SEC form 8
2025-10-28 20:08 ET
Arcus Biosciences published news for 2025 q3
SEC form 8
2025-10-28 20:08 ET
Arcus Biosciences reported for 2025 q3
SEC form 10
2025-08-06 20:13 ET
Arcus Biosciences reported for 2025 q2
SEC form 8
2025-08-06 20:09 ET
Arcus Biosciences published news for 2025 q2
SEC form 8
2025-08-06 20:09 ET
Arcus Biosciences reported for 2025 q2
SEC form 8
2025-06-12 20:21 ET
Arcus Biosciences published news for 2025 q1
SEC form 8
2025-06-12 20:21 ET
Arcus Biosciences published news for 2025 q1
SEC form 10
2025-05-06 20:12 ET
Arcus Biosciences published news for 2025 q1
SEC form 8
2025-05-06 20:09 ET
Arcus Biosciences published news for 2025 q1
SEC form 8
2025-05-06 20:09 ET
Arcus Biosciences reported for 2025 q1
SEC form 10
2025-05-06 00:00 ET
Arcus Biosciences published news for 2025 q1
SEC form 10
2025-02-25 16:09 ET
Arcus Biosciences published news for 2024 q4
SEC form 8
2025-02-25 16:07 ET
Arcus Biosciences published news for 2024 q4
SEC form 8
2025-02-25 16:07 ET
Arcus Biosciences reported for 2024 q4
SEC form 10
2025-02-25 00:00 ET
Arcus Biosciences published news for 2024 q4
SEC form 8
2025-02-19 21:05 ET
Arcus Biosciences published news for 2024 q4
SEC form 8
2025-02-19 21:05 ET
Arcus Biosciences published news for 2024 q4
SEC form 8
2025-02-19 21:05 ET
Arcus Biosciences published news for 2024 q4
SEC form 8
2025-02-18 00:00 ET
Arcus Biosciences published news for 2024 q4
SEC form 10
2024-11-06 16:25 ET
Arcus Biosciences reported for 2024 q3
SEC form 8
2024-11-06 16:23 ET
Arcus Biosciences published news for 2024 q3
SEC form 8
2024-11-06 16:23 ET
Arcus Biosciences published news for 2024 q3
SEC form 10
2024-08-08 16:15 ET
Arcus Biosciences reported for 2024 q2
SEC form 8
2024-08-08 16:09 ET
Arcus Biosciences published news for 2024 q2
SEC form 8
2024-08-08 16:09 ET
Arcus Biosciences reported for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Arcus Biosciences reported for 2024 q2
SEC form 10
2024-05-08 00:00 ET
Arcus Biosciences published news for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Arcus Biosciences published news for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Arcus Biosciences reported for 2024 q1
SEC form 10
2024-02-21 16:16 ET
Arcus Biosciences published news for 2023 q4
SEC form 8
2024-02-21 16:08 ET
Arcus Biosciences published news for 2023 q4
SEC form 8
2024-02-21 16:08 ET
Arcus Biosciences reported for 2023 q4
SEC form 10
2024-02-21 00:00 ET
Arcus Biosciences published news for 2023 q4
SEC form 10
2023-11-07 16:11 ET
Arcus Biosciences reported for 2023 q3
SEC form 8
2023-11-07 16:04 ET
Arcus Biosciences published news for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Arcus Biosciences published news for 2023 q3
SEC form 10
2023-08-07 08:13 ET
Arcus Biosciences reported for 2023 q2
SEC form 6
2023-08-07 08:08 ET
Arcus Biosciences published news for 2023 q2
SEC form 10
2023-08-07 00:00 ET
Arcus Biosciences published news for 2023 q2
SEC form 8
2023-08-07 00:00 ET
Arcus Biosciences published news for 2023 q2
SEC form 6
2023-06-28 08:25 ET
Arcus Biosciences published news for 2023 q1
SEC form 6
2023-06-16 16:19 ET
Arcus Biosciences published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Arcus Biosciences published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Arcus Biosciences published news for 2023 q1
SEC form 6
2023-03-10 16:46 ET
Arcus Biosciences published news for 2022 q4
SEC form 10
2023-02-28 16:18 ET
Arcus Biosciences reported for 2022 q4
SEC form 6
2023-02-28 16:11 ET
Arcus Biosciences published news for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Arcus Biosciences reported for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Arcus Biosciences reported for 2022 q4
SEC form 6
2022-12-19 17:05 ET
Arcus Biosciences published news for 2022 q3
SEC form 6
2022-11-28 08:39 ET
Arcus Biosciences published news for 2022 q3
SEC form 10
2022-11-02 16:11 ET
Arcus Biosciences reported for 2022 q3
SEC form 6
2022-11-02 16:05 ET
Arcus Biosciences published news for 2022 q3
SEC form 10
2022-11-02 00:00 ET
Arcus Biosciences reported for 2022 q3
SEC form 8
2022-11-02 00:00 ET
Arcus Biosciences reported for 2022 q3
SEC form 6
2022-10-11 16:13 ET
Arcus Biosciences published news for 2022 q3
SEC form 10
2022-08-03 16:22 ET
Arcus Biosciences reported for 2022 q2
SEC form 6
2022-08-03 16:16 ET
Arcus Biosciences published news for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Arcus Biosciences reported for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Arcus Biosciences reported for 2022 q2
SEC form 6
2022-06-16 16:14 ET
Arcus Biosciences published news for 2022 q1
SEC form 10
2022-05-09 16:15 ET
Arcus Biosciences reported for 2022 q1
SEC form 6
2022-05-09 16:08 ET
Arcus Biosciences published news for 2022 q1
SEC form 10
2022-05-09 00:00 ET
Arcus Biosciences reported for 2022 q1
SEC form 8
2022-05-09 00:00 ET
Arcus Biosciences reported for 2022 q1
SEC form 6
2022-04-20 16:12 ET
Arcus Biosciences published news for 2022 q1
SEC form 10
2022-02-23 16:16 ET
Arcus Biosciences published news for 2021 q4
SEC form 6
2022-02-23 16:08 ET
Arcus Biosciences published news for 2021 q4
SEC form 10
2022-02-23 00:00 ET
Arcus Biosciences published news for 2021 q4
SEC form 8
2022-02-23 00:00 ET
Arcus Biosciences published news for 2021 q4
SEC form 6
2021-12-21 16:40 ET
Arcus Biosciences published news for 2021 q3
SEC form 6
2021-11-18 07:06 ET
Arcus Biosciences published news for 2021 q3
SEC form 6
2021-11-08 17:11 ET
Arcus Biosciences published news for 2021 q3
SEC form 10
2021-11-08 16:16 ET
Arcus Biosciences published news for 2021 q3
SEC form 10
2021-11-08 00:00 ET
Arcus Biosciences published news for 2021 q3
SEC form 8
2021-11-08 00:00 ET
Arcus Biosciences published news for 2021 q3
SEC form 6
2021-08-11 16:33 ET
Arcus Biosciences published news for 2021 q2
SEC form 10
2021-08-05 16:19 ET
Arcus Biosciences published news for 2021 q2
SEC form 6
2021-08-05 16:13 ET
Arcus Biosciences published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Arcus Biosciences published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Arcus Biosciences published news for 2021 q2
SEC form 6
2021-07-19 16:47 ET
Arcus Biosciences published news for 2021 q2
SEC form 6
2021-06-07 16:26 ET
Arcus Biosciences published news for 2021 q1
SEC form 10
2021-05-05 16:19 ET
Arcus Biosciences published news for 2021 q1
SEC form 6
2021-05-05 16:13 ET
Arcus Biosciences published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Arcus Biosciences published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
Arcus Biosciences published news for 2021 q1
SEC form 6
2021-04-26 16:24 ET
Arcus Biosciences published news for 2021 q1
SEC form 6
2021-04-20 16:09 ET
Arcus Biosciences published news for 2021 q1
SEC form 6
2021-04-16 19:02 ET
Arcus Biosciences published news for 2021 q1
SEC form 6
2021-03-16 16:06 ET
Arcus Biosciences published news for 2020 q4
SEC form 10
2021-02-24 19:10 ET
Arcus Biosciences published news for 2020 q4
SEC form 6
2021-02-24 16:13 ET
Arcus Biosciences published news for 2020 q4
SEC form 6
2021-02-01 08:08 ET
Arcus Biosciences published news for 2020 q4
SEC form 6
2021-01-06 16:15 ET
Arcus Biosciences published news for 2020 q4
SEC form 6
2020-12-18 16:13 ET
Arcus Biosciences published news for 2020 q3
SEC form 10
2020-11-05 16:25 ET
Arcus Biosciences published news for 2020 q3
SEC form 6
2020-11-05 16:16 ET
Arcus Biosciences published news for 2020 q3
SEC form 6
2020-10-01 16:50 ET
Arcus Biosciences published news for 2020 q3